Health & wellness
“I refuse to let lupus get me down”
Diagnosed with systemic lupus erythematosus (SLE) almost two decades ago, Laurie Bean has chosen a lifestyle that helps her battle debilitating side effects and the emotional fallout of this autoantibody disease.
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments.
3 nurse practitioners who are filling critical gaps in healthcare
From using cutting-edge technology to address mental health issues to launching an urban clinic that helps treat substance-abuse disorders and taking an innovative approach to deliver rural medical care, learn how Johnson & Johnson is helping support a new generation of providers.
Do you know what heart failure is? (Hint: It’s probably not what you think)
Learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
Featured stories
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.
What is head and neck cancer?
This complex type of cancer can cause malignancies of the mouth, throat, larynx and nasal cavity. Find out how Johnson & Johnson is innovating to change the current treatment paradigm.
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
What are alloantibodies?
Learn how Johnson & Johnson is investigating a therapy for two alloantibody-driven diseases that can affect the lives of developing fetuses and newborn babies.
